[vc_empty_space][vc_empty_space]
Effect of drug treatment on serum Cartilage Oligomeric Matrix Protein levels in patients of Rheumatoid Arthritis and Knee Osteoarthritis in Bandung, Indonesia
Saptarini N.M.a, Hadisoebroto G.b, Wibowo M.S.c, Gusdinar T.c
a Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, 45363, Indonesia
b Department of Pharmacy, Faculty of Mathematics and Natural Sciences, Universitas Al Ghifari, Bandung, 40293, Indonesia
c Department of Physicochemistry, School of Pharmacy, Institut Teknologi Bandung, Bandung, 40243, Indonesia
[vc_row][vc_column][vc_row_inner][vc_column_inner][vc_separator css=”.vc_custom_1624529070653{padding-top: 30px !important;padding-bottom: 30px !important;}”][/vc_column_inner][/vc_row_inner][vc_row_inner layout=”boxed”][vc_column_inner width=”3/4″ css=”.vc_custom_1624695412187{border-right-width: 1px !important;border-right-color: #dddddd !important;border-right-style: solid !important;border-radius: 1px !important;}”][vc_empty_space][megatron_heading title=”Abstract” size=”size-sm” text_align=”text-left”][vc_column_text]© 2020 Journal of Advanced Pharmacy Education & Research.Joint illnesses such as rheumatoid arthritis (RA) and knee osteoarthritis (OA) are defined by the destruction of articular cartilage and changes of the underlying bone. Enhanced proteolysis of molecules bound to and exposed at the surface of collagen, such as cartilage oligomeric matrix protein (COMP) will make an imbalance in the turnover of matrix proteins. The objective of this investigation was to analyze the influence of drug treatment on COMP levels of treated RA and knee OA patients. The subjects were RA patients who visited the rheumatology clinic at one public hospital and knee OA patients who visited the Orthopedic clinics of a private hospital in Bandung, Indonesia. Prescribed drugs were collected utilizing interviews. COMP levels were measured by enzyme-linked immunosorbent assay. The COMP levels of RA patients, knee OA patients, and normal individuals were 873.16 ± 165.6, 911.43 ± 227.34, and 927.26 ± 90.38 ng/mL, respectively. There was no significant difference in the COMP level (p = 0.47) among the groups. Mostly, RA patients were treated with single or combined disease-modified antirheumatic drugs, while most of the knee OA patients were treated with glucosamine and chondroitin. Drug treatment maintained the serum COMP levels of RA and knee OA patients.[/vc_column_text][vc_empty_space][vc_separator css=”.vc_custom_1624528584150{padding-top: 25px !important;padding-bottom: 25px !important;}”][vc_empty_space][megatron_heading title=”Author keywords” size=”size-sm” text_align=”text-left”][vc_column_text][/vc_column_text][vc_empty_space][vc_separator css=”.vc_custom_1624528584150{padding-top: 25px !important;padding-bottom: 25px !important;}”][vc_empty_space][megatron_heading title=”Indexed keywords” size=”size-sm” text_align=”text-left”][vc_column_text]Arthritis,ELISA,Maintained COMP,Serum,Treated patient[/vc_column_text][vc_empty_space][vc_separator css=”.vc_custom_1624528584150{padding-top: 25px !important;padding-bottom: 25px !important;}”][vc_empty_space][megatron_heading title=”Funding details” size=”size-sm” text_align=”text-left”][vc_column_text][/vc_column_text][vc_empty_space][vc_separator css=”.vc_custom_1624528584150{padding-top: 25px !important;padding-bottom: 25px !important;}”][vc_empty_space][megatron_heading title=”DOI” size=”size-sm” text_align=”text-left”][vc_column_text][/vc_column_text][/vc_column_inner][vc_column_inner width=”1/4″][vc_column_text]Widget Plumx[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row][vc_column][vc_separator css=”.vc_custom_1624528584150{padding-top: 25px !important;padding-bottom: 25px !important;}”][/vc_column][/vc_row]